The Episodic Ataxia Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Episodic Ataxia Treatment Market:
https://www.thebusinessresearchcompany.com/report/episodic-ataxia-treatment-global-market-report
According to The Business Research Company’s Episodic Ataxia Treatment Global Market Report 2024, The episodic ataxia treatment market size has grown strongly in recent years. It will grow from $10.41 billion in 2023 to $11.07 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to an increasing understanding of genetic causes, increasing funding for rare disease research, increasing availability of specialized clinics, rising awareness of personalized medicine, and growth in clinical trial participation.
The episodic ataxia treatment market size is expected to see strong growth in the next few years. It will grow to $14.29 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing genetic testing accessibility, rising demand for genetic counseling services, growing number of clinical trials, increasing number of patient registries, and increasing investment in rare disease biobanks. Major trends in the forecast period include technological advancements, personalized medicine, telemedicine, stem cell therapy, and telerehabilitation services.
The increasing prevalence of neurological disorders is expected to propel the growth of the episodic ataxia treatment market going forward. Neurological disorders are diseases that affect the central and peripheral nervous systems, including the brain, spinal cord, cranial and peripheral nerves, autonomic nervous system, nerve roots, neuromuscular junction, and muscles. The increasing prevalence of neurological disorders can be attributed to several factors, including the aging population, genetic factors, and infectious diseases. Episodic ataxia treatment is used in neurological disorders to address the symptoms and improve the management of conditions involving intermittent loss of coordination and balance. For instance, in April 2022, according to the European Brain Council, a Belgium-based non-profit organization, Dementia (a progressive neurological disorder) affected 10.5 million people in Europe in 2022 and is expected to grow to 18.7 million by 2050. Therefore, the increasing prevalence of neurological disorders is driving the episodic ataxia treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=18353&type=smp
The episodic ataxia treatment market covered in this report is segmented –
1) By Type: Ataxia telangiectasia, Episodic ataxia, Spinocerebullar ataxia, Friedreich’s ataxia, Other Types
2) By Treatment: Medications, Levodopa, Pramipexole, Venlafaxine, Other Treatments
3) By Route of Administration: Oral, Parenteral, Other Routes of Administration
4) By Distribution Channel: Direct Tender, Retail Sales, Other Distribution Channels
5) By End User: Hospital, Clinics, Home Healthcare, Other End Users
Major companies operating in the episodic ataxia treatment market are focused on developing innovative solutions, such as Friedreich’s ataxia (FA) treatment to enhance patient outcomes and address the unmet needs associated with this rare neurological condition. Episodic ataxia (EA) is a rare neurological disorder characterized by intermittent episodes of ataxia and a lack of voluntary coordination of muscle movements. These episodes can be brief or prolonged and vary in frequency and severity. For instance, in February 2024, Biogen Inc., a US-based biotechnology company, announced the approval of SKYCLARYS (omaveloxolone) for treating Friedreich’s ataxia (FA). Omaveloxolone addresses the underlying mitochondrial dysfunction associated with FA, potentially altering the disease’s progression rather than merely alleviating symptoms. The therapy acts as a potent transcriptional modulator, which helps restore mitochondrial function and cellular energy production.
The episodic ataxia treatment market report table of contents includes:
1. Executive Summary
2. Episodic Ataxia Treatment Market Characteristics
3. Episodic Ataxia Treatment Market Trends And Strategies
4. Episodic Ataxia Treatment Market – Macro Economic Scenario
5. Global Episodic Ataxia Treatment Market Size and Growth
.
.
.
32. Global Episodic Ataxia Treatment Market Competitive Benchmarking
33. Global Episodic Ataxia Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Episodic Ataxia Treatment Market
35. Episodic Ataxia Treatment Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
